Semaglutide / Cagrilintide

Semaglutide / Cagrilintide pairs the established GLP-1 receptor agonist semaglutide with cagrilintide, a long-acting acylated analogue of the pancreatic hormone amylin. This combination exploits two mechanistically distinct but convergent pathways governing energy homeostasis — an approach grounded in the physiological observation that GLP-1 and amylin activate separate but overlapping neuronal populations within the area postrema and nucleus tractus solitarius of the hindbrain.

Amylin, co-secreted with insulin from pancreatic beta cells in response to nutrient intake, signals through calcitonin receptors complexed with receptor activity-modifying proteins (RAMPs) to slow gastric emptying, suppress post-prandial glucagon secretion, and reduce meal size through central satiety signaling. Cagrilintide's structural modifications — fatty acid acylation enabling albumin binding — extend its half-life to support once-weekly dosing while preserving the native signaling profile.

The dual GLP-1/amylin agonism framework addresses a limitation of mono-receptor approaches: compensatory upregulation of alternative appetite-stimulating pathways. By engaging both incretin and amylin receptor systems simultaneously, this combination has demonstrated additive weight reduction effects in clinical research exceeding those observed with either agent administered independently. ROEHN supplies this formulation at 99% HPLC-verified purity as a lyophilized powder, supporting translational research into next-generation multi-receptor metabolic pharmacology.